Plain-English translation of NCT07629245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study tests a new treatment using cryopreserved autologous stromal vascular fraction (cells harvested from your own fat tissue and frozen for later use) combined with a surgical technique to treat hard-to-heal fistulas caused by Crohn's disease. The frozen cells are thawed and injected directly into the fistula area to help your body repair the damage. Researchers are checking whether this treatment is safe and effective for patients whose fistulas haven't healed with standard care.
Some people with Crohn's disease develop painful fistulas (abnormal tunnels between the bowel and skin) that don't respond well to current treatments and keep coming back. This trial explores whether using cells from a patient's own fat tissue might help the body heal these stubborn fistulas and prevent them from returning.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive an injection of your thawed cells directly into the fistula area under anesthesia. The procedure involves surgical preparation of the fistula before the cell injection. You'll be monitored for safety and effectiveness through follow-up visits and imaging tests (like MRI scans). The trial enrolls 25 patients across multiple centers in France, and your participation allows researchers to gather important safety and effectiveness information on this new approach.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
France